BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 29.6] [Reference Citation Analysis]
Number Citing Articles
1 Zullo A, Soncini M, Bucci C, Marmo R; Gruppo Italiano per lo Studio dell'Emorragia Digestiva (GISED) (Appendix). Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: A prospective, multicenter cohort study. J Gastroenterol Hepatol 2021. [PMID: 34189770 DOI: 10.1111/jgh.15601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Boucherie Q, Rouby F, Frankel D, Roll P, Micallef J. Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database. Therapie 2018;73:385-8. [PMID: 29778306 DOI: 10.1016/j.therap.2018.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
3 Zullo A, Manta R, De Francesco V, Fiorini G, Hassan C, Vaira D. Diagnostic yield of upper endoscopy according to appropriateness: A systematic review. Dig Liver Dis 2019;51:335-9. [PMID: 30583999 DOI: 10.1016/j.dld.2018.11.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology 2020;59:e1-e23. [DOI: 10.1093/rheumatology/kez672] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 40.0] [Reference Citation Analysis]
5 Greiwe J, Cooke A, Nanda A, Epstein SZ, Wasan AN, Shepard KV 2nd, Capão-Filipe M, Nish A, Rubin M, Gregory KL, Dass K, Blessing-Moore J, Randolph C. Work Group Report: Perspectives in Diagnosis and Management of Exercise-Induced Bronchoconstriction in Athletes. J Allergy Clin Immunol Pract 2020;8:2542-55. [PMID: 32636147 DOI: 10.1016/j.jaip.2020.05.020] [Reference Citation Analysis]
6 Franchi C, Mannucci PM, Nobili A, Ardoino I. Use and prescription appropriateness of drugs for peptic ulcer and gastrooesophageal reflux disease in hospitalized older people. Eur J Clin Pharmacol 2020;76:459-65. [PMID: 31853593 DOI: 10.1007/s00228-019-02815-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Anzić S, Turkalj M, Župan A, Labor M, Plavec D, Baudoin T. Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms: Randomised, double-blind, placebo-controlled trial. Clin Otolaryngol 2018;43:496-501. [DOI: 10.1111/coa.13005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 M ZA, Lavu A, Ansari M, V RA, Vilakkathala R. A Cross-Sectional Study on Single-Day Use of Proton Pump Inhibitors in Tertiary Care Hospitals of South India. Hosp Pharm 2021;56:109-15. [PMID: 33790486 DOI: 10.1177/0018578719873876] [Reference Citation Analysis]
9 Wilson JM, McGowan EC. Diagnosis and Management of Eosinophilic Esophagitis. Immunol Allergy Clin North Am 2018;38:125-39. [PMID: 29132668 DOI: 10.1016/j.iac.2017.09.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Liatsos C, Rokkas T. The Effect of Chronic Use of Proton Pump Inhibitors on Gastric Cancer: Should We Be Aware of It? Dig Dis 2018;36:395-6. [DOI: 10.1159/000489629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology. 2018;154:302-318. [PMID: 28827081 DOI: 10.1053/j.gastro.2017.07.049] [Cited by in Crossref: 109] [Cited by in F6Publishing: 74] [Article Influence: 27.3] [Reference Citation Analysis]
12 Thompson W, Nissen M, Haastrup P, Le JV, Lundby C, Nielsen JB, Jarbøl DE. Discussing proton pump inhibitor deprescribing: the views of Danish GPs and older patients. BMC Fam Pract 2020;21:160. [PMID: 32770959 DOI: 10.1186/s12875-020-01227-5] [Reference Citation Analysis]
13 Voukelatou P, Vrettos I, Emmanouilidou G, Dodos K, Skotsimara G, Kontogeorgou D, Kalliakmanis A. Predictors of Inappropriate Proton Pump Inhibitors Use in Elderly Patients. Curr Gerontol Geriatr Res 2019;2019:7591045. [PMID: 30713553 DOI: 10.1155/2019/7591045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
14 Sim W, Jain SR, Lim WH, Chin YH, Ng CH, Syn N, Goh KS, Soo R, Wang L, Goh BC. Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res 2021;10:3567-81. [PMID: 34584857 DOI: 10.21037/tlcr-21-378] [Reference Citation Analysis]
15 Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330-93. [PMID: 29562325 DOI: 10.1093/eurheartj/ehy136] [Cited by in Crossref: 935] [Cited by in F6Publishing: 645] [Article Influence: 467.5] [Reference Citation Analysis]
16 Scarpignato C, Sloan JA, Wang DH, Hunt RH. Gastrointestinal pharmacology: practical tips for the esophagologist. Ann N Y Acad Sci 2020;1481:90-107. [PMID: 32822080 DOI: 10.1111/nyas.14447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zullo A, De Francesco V, Vaira D. Is Double-Dose Esomeprazole With Bismuth Really Safe? American Journal of Gastroenterology 2017;112:1894-5. [DOI: 10.1038/ajg.2017.386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Ni X, Lin M, Li J, Zeng L, Li W, Huang L, Li D, Zhang L. Development of an evaluation indicator system for the rational use of proton pump inhibitors in pediatric intensive care units: An application of Delphi method. Medicine (Baltimore) 2021;100:e26327. [PMID: 34128875 DOI: 10.1097/MD.0000000000026327] [Reference Citation Analysis]
19 Hunt RH, Scarpignato C. Potent Acid Suppression with PPIs and P-CABs: What’s New? Curr Treat Options Gastro 2018;16:570-90. [DOI: 10.1007/s11938-018-0206-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
20 Tommasi S, Elliot DJ, Hulin JA, Lewis BC, McEvoy M, Mangoni AA. Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance. Sci Rep 2017;7:2871. [PMID: 28588208 DOI: 10.1038/s41598-017-03069-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Tolone S, De Bortoli N, Frazzoni M, Savarino E. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev Clin Pharmacol 2020;13:437-49. [PMID: 32253948 DOI: 10.1080/17512433.2020.1752664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
22 Ng HS, Koczwara B, Roder DM, Niyonsenga T, Vitry AI. Comorbidities in Australian women with hormone‐dependent breast cancer: a population‐based analysis. Medical Journal of Australia 2018;208:24-8. [DOI: 10.5694/mja17.00006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
23 Radhamanalan R, Alagumuthu M, Nagaraju N. Synthesis and drug efficacy validations of racemic-substituted benzimidazoles as antiulcer/antigastric secretion agents. Future Medicinal Chemistry 2018;10:1805-20. [DOI: 10.4155/fmc-2017-0214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
24 Paliwal P, Kumar AS, Tripathi H, Singh S, Patne SC, Krishnamurthy S. Pharmacological application of barium containing bioactive glass in gastro-duodenal ulcers. Materials Science and Engineering: C 2018;92:424-34. [DOI: 10.1016/j.msec.2018.06.068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563. [PMID: 33589415 DOI: 10.1136/bmjgast-2020-000563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Chen F, He X, Fang B, Wang S. Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use. Drug Des Devel Ther 2020;14:5689-98. [PMID: 33380789 DOI: 10.2147/DDDT.S279302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Schnoll-sussman F, Niec R, Katz PO. Proton Pump Inhibitors. Gastrointestinal Endoscopy Clinics of North America 2020;30:239-51. [DOI: 10.1016/j.giec.2019.12.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
28 Steinbach EC, Hernandez M, Dellon ES. Eosinophilic Esophagitis and the Eosinophilic Gastrointestinal Diseases: Approach to Diagnosis and Management. J Allergy Clin Immunol Pract 2018;6:1483-95. [PMID: 30201096 DOI: 10.1016/j.jaip.2018.06.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
29 Bhatia SJ, Makharia GK, Abraham P, Bhat N, Kumar A, Reddy DN, Ghoshal UC, Ahuja V, Rao GV, Devadas K, Dutta AK, Jain A, Kedia S, Dama R, Kalapala R, Alvares JF, Dadhich S, Dixit VK, Goenka MK, Goswami BD, Issar SK, Leelakrishnan V, Mallath MK, Mathew P, Mathew P, Nandwani S, Pai CG, Peter L, Prasad AVS, Singh D, Sodhi JS, Sud R, Venkataraman J, Midha V, Bapaye A, Dutta U, Jain AK, Kochhar R, Puri AS, Singh SP, Shimpi L, Sood A, Wadhwa RT. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol 2019;38:411-40. [PMID: 31802441 DOI: 10.1007/s12664-019-00979-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
30 Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [PMID: 31838548 DOI: 10.1007/s00228-019-02810-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
31 Savarino V, Tosetti C, Benedetto E, Compare D, Nardone G. Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) - Study section "Digestive Diseases in Primary Care". Dig Liver Dis 2018;50:894-902. [PMID: 30093304 DOI: 10.1016/j.dld.2018.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
32 Motter FR, Hilmer SN, Paniz VMV. Pain and Inflammation Management in Older Adults: A Brazilian Consensus of Potentially Inappropriate Medication and Their Alternative Therapies. Front Pharmacol 2019;10:1408. [PMID: 31849664 DOI: 10.3389/fphar.2019.01408] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, Katelaris P, Tutuian RI, Castell DO. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs 2017;77:547-61. [PMID: 28233274 DOI: 10.1007/s40265-017-0712-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
34 Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, Chiriac SA, Ciobica A, Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol 2017; 23(35): 6500-6515 [PMID: 29085200 DOI: 10.3748/wjg.v23.i35.6500] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 84] [Article Influence: 25.5] [Reference Citation Analysis]
35 Fiorini G, Zullo A, Saracino IM, Gatta L, Pavoni M, Vaira D. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. Eur J Gastroenterol Hepatol. 2018;30:621-625. [PMID: 29481383 DOI: 10.1097/meg.0000000000001102] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
36 Yadlapati R, Kahrilas PJ. The "dangers" of chronic proton pump inhibitor use. J Allergy Clin Immunol 2018;141:79-81. [PMID: 28729001 DOI: 10.1016/j.jaci.2017.06.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
37 Lahner E, Carabotti M, Esposito G, Hassan C, Zullo A, Annibale B. Occurrence and predictors of metaplastic atrophic gastritis in a nation-wide consecutive endoscopic population presenting with upper gastrointestinal symptoms. European Journal of Gastroenterology & Hepatology 2018;30:1291-6. [DOI: 10.1097/meg.0000000000001246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Albarqouni L, Moynihan R, Clark J, Scott AM, Duggan A, Del Mar C. Head of bed elevation to relieve gastroesophageal reflux symptoms: a systematic review. BMC Fam Pract 2021;22:24. [PMID: 33468060 DOI: 10.1186/s12875-021-01369-0] [Reference Citation Analysis]
39 Dharmarajan TS. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing. J Am Med Dir Assoc 2021;22:15-22. [PMID: 33321078 DOI: 10.1016/j.jamda.2020.09.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
40 Gamelas V, Salvado V, Dias L. Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol 2019;26:114-20. [PMID: 30976616 DOI: 10.1159/000488506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
41 Conte C, Bourrel R, Despas F, Lapeyre-Mestre M. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midi-Pyrénées region. Fundam Clin Pharmacol 2019;33:327-38. [PMID: 30625254 DOI: 10.1111/fcp.12436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 da Rosa TF, Foletto VS, Serafin MB, Bottega A, Hörner R. Anti-infective properties of proton pump inhibitors: perspectives. Int Microbiol 2021. [PMID: 34476634 DOI: 10.1007/s10123-021-00203-y] [Reference Citation Analysis]
43 Pironi L, Raschi E, Sasdelli AS. The safety of available treatment options for short bowel syndrome and unmet needs. Expert Opin Drug Saf 2021;:1-13. [PMID: 34105428 DOI: 10.1080/14740338.2021.1940947] [Reference Citation Analysis]
44 Scarpignato C, Gatta L. Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. In: Morice AH, Dettmar PW, editors. Reflux Aspiration and Lung Disease. Cham: Springer International Publishing; 2018. pp. 269-91. [DOI: 10.1007/978-3-319-90525-9_23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
45 Shin MR, An HJ, Seo BI, Roh SS. Anti-apoptotic effect of banhasasim-tang on chronic acid reflux esophagitis. World J Gastroenterol 2017; 23(25): 4644-4653 [PMID: 28740353 DOI: 10.3748/wjg.v23.i25.4644] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
46 Eltahir HM, Nazmy MH. Esomeprazole ameliorates CCl4 induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers. Biomed Pharmacother 2018;97:1356-65. [PMID: 29156525 DOI: 10.1016/j.biopha.2017.11.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
47 Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P, Savarino E. Latest insights into the hot question of proton pump inhibitor safety - a narrative review. Dig Liver Dis. 2020;52:842-852. [PMID: 32513631 DOI: 10.1016/j.dld.2020.04.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
48 Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. J Pain Res. 2018;11:361-374. [PMID: 29491719 DOI: 10.2147/jpr.s156938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
49 Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, Vaira D. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-9. [DOI: 10.1111/apt.14597] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]
50 Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use appropriate? BMC Med 2017;15:36. [PMID: 28219434 DOI: 10.1186/s12916-017-0804-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
51 Khilnani P, Rawal N, Singha C. Gastrointestinal Issues in Critically Ill Children. Indian J Crit Care Med 2020;24:S201-4. [PMID: 33354042 DOI: 10.5005/jp-journals-10071-23637] [Reference Citation Analysis]
52 Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology. 2018;. [PMID: 30289992 DOI: 10.1002/hep.30304] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
53 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Stasi E, Michielan A, Morreale GC, Tozzi A, Venezia L, Bortoluzzi F, Triossi O, Soncini M, Leandro G, Milazzo G, Anderloni A. Five common errors to avoid in clinical practice: the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) Choosing Wisely Campaign. Intern Emerg Med 2019;14:301-8. [PMID: 30499071 DOI: 10.1007/s11739-018-1992-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Sharma R, Roy A, Ramos C, Rosenberg R, Garcia-Carrasquillo R, Lebwohl B. Low adherence to national guidelines for proton-pump inhibitor prescription in patients receiving combination aspirin and anticoagulation. Therap Adv Gastroenterol 2017;10:387-96. [PMID: 28507597 DOI: 10.1177/1756283X17694807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
56 Xavier S, Magalhães J, Cotter J. Proton Pump Inhibitors: Are They a Real Threat to the Patient? GE Port J Gastroenterol 2018;25:243-52. [PMID: 30320163 DOI: 10.1159/000487154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
57 Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Current Opinion in Gastroenterology 2019;35:344-55. [DOI: 10.1097/mog.0000000000000543] [Cited by in Crossref: 12] [Article Influence: 6.0] [Reference Citation Analysis]
58 Leitinger E, Hui L, Grigg A. Is there a role for proton pump inhibitor prophylaxis in haematology patients? Intern Med J 2019;49:694-701. [PMID: 30719802 DOI: 10.1111/imj.14241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
60 Poly T, Islam M, Yang H, Wu C, Li Y. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int 2019;30:103-14. [DOI: 10.1007/s00198-018-4788-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 16.0] [Reference Citation Analysis]
61 Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. The appropriate use of proton-pump inhibitors. Minerva Med 2018;109. [DOI: 10.23736/s0026-4806.18.05705-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 7.7] [Reference Citation Analysis]
62 Colombo F, Nunnari P, Ceccarelli G, Romano AV, Barbieri P, Scaglione F. Measures of Drug Prescribing at Care Transitions in an Internal Medicine Unit. J Clin Pharmacol 2018;58:1171-83. [PMID: 29723431 DOI: 10.1002/jcph.1123] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
63 Gyawali CP, Azagury DE, Chan WW, Chandramohan SM, Clarke JO, Bortoli N, Figueredo E, Fox M, Jodorkovsky D, Lazarescu A, Malfertheiner P, Martinek J, Murayama KM, Penagini R, Savarino E, Shetler KP, Stein E, Tatum RP, Wu J. Nonerosive reflux disease: clinical concepts. Ann N Y Acad Sci 2018;1434:290-303. [DOI: 10.1111/nyas.13845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
64 Vinke P, Wesselink E, van Orten-Luiten W, van Norren K. The Use of Proton Pump Inhibitors May Increase Symptoms of Muscle Function Loss in Patients with Chronic Illnesses. Int J Mol Sci 2020;21:E323. [PMID: 31947724 DOI: 10.3390/ijms21010323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
66 Pesek RD, Gupta SK. Emerging drugs for eosinophilic esophagitis. Expert Opin Emerg Drugs. 2018;23:173-183. [PMID: 29848130 DOI: 10.1080/14728214.2018.1483335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
67 Aronson JK. Inhibiting the proton pump: mechanisms, benefits, harms, and questions. BMC Med 2016;14:172. [PMID: 27825384 DOI: 10.1186/s12916-016-0724-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
68 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 96] [Cited by in F6Publishing: 72] [Article Influence: 24.0] [Reference Citation Analysis]
69 Svanström H, Lund M, Melbye M, Pasternak B. Use of Proton Pump Inhibitors and the Risk of Acute Kidney Injury Among Patients with Rheumatoid Arthritis: Cohort Study. Drug Saf 2018;41:817-26. [PMID: 29603109 DOI: 10.1007/s40264-018-0663-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
70 Spechler SJ. Proton Pump Inhibitors: What the Internist Needs to Know. Med Clin North Am 2019;103:1-14. [PMID: 30466666 DOI: 10.1016/j.mcna.2018.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
71 Tozzi M, Sørensen CE, Magni L, Christensen NM, Bouazzi R, Buch CM, Stefanini M, Duranti C, Arcangeli A, Novak I. Proton Pump Inhibitors Reduce Pancreatic Adenocarcinoma Progression by Selectively Targeting H+, K+-ATPases in Pancreatic Cancer and Stellate Cells. Cancers (Basel) 2020;12:E640. [PMID: 32164284 DOI: 10.3390/cancers12030640] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
72 Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017;3:CD011194. [PMID: 28271513 DOI: 10.1002/14651858.CD011194.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
73 Avraham O, Biglow M. Implementation of Proton Pump Inhibitor Deprescription Protocol in Geriatric Residents. Ann Pharmacother 2018;52:747-53. [PMID: 29473423 DOI: 10.1177/1060028018759747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
74 Shin MR, Seo BI, Son CG, Roh SS, An HJ. Banhasasim-Tang Treatment Reduces the Severity of Esophageal Mucosal Ulcer on Chronic Acid Reflux Esophagitis in Rats. Biomed Res Int 2017;2017:7157212. [PMID: 28349065 DOI: 10.1155/2017/7157212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
75 Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord 2018;19:145-58. [PMID: 29464446 DOI: 10.1007/s11154-018-9443-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
76 Schmulson MJ, Frati-Munari AC. Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. Rev Gastroenterol Mex. 2019;84:44-51. [PMID: 29678362 DOI: 10.1016/j.rgmx.2018.02.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
77 Naunton M, Peterson GM, Deeks LS, Young H, Kosari S. We have had a gutful: The need for deprescribing proton pump inhibitors. J Clin Pharm Ther 2018;43:65-72. [PMID: 28895169 DOI: 10.1111/jcpt.12613] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
78 Kavitt RT, Lipowska AM, Anyane-yeboa A, Gralnek IM. Diagnosis and Treatment of Peptic Ulcer Disease. The American Journal of Medicine 2019;132:447-56. [DOI: 10.1016/j.amjmed.2018.12.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
79 Kahrilas P, Yadlapati R, Roman S. Emerging dilemmas in the diagnosis and management of gastroesophageal reflux disease. F1000Res 2017;6:1748. [PMID: 29034088 DOI: 10.12688/f1000research.11918.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Broide E, Eindor-Abarbanel A, Shirin H, Richter V, Matalon S, Leshno M. Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice. BMJ Open 2020;10:e031091. [PMID: 32051298 DOI: 10.1136/bmjopen-2019-031091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Walker MJ, Crews NR, El-Halabi M, Fayad NF. Educational Intervention Improves Proton Pump Inhibitor Stewardship in Outpatient Gastroenterology Clinics. Gastroenterology Res 2019;12:305-11. [PMID: 31803310 DOI: 10.14740/gr1238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Durán C, Ciucci S, Palladini A, Ijaz UZ, Zippo AG, Sterbini FP, Masucci L, Cammarota G, Ianiro G, Spuul P, Schroeder M, Grill SW, Parsons BN, Pritchard DM, Posteraro B, Sanguinetti M, Gasbarrini G, Gasbarrini A, Cannistraci CV. Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. Nat Commun 2021;12:1926. [PMID: 33771992 DOI: 10.1038/s41467-021-22135-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
83 Sasaki T, Mori S, Kishi S, Fujiwara-Tani R, Ohmori H, Nishiguchi Y, Hojo Y, Kawahara I, Nakashima C, Fujii K, Luo Y, Kuniyasu H. Effect of Proton Pump Inhibitors on Colorectal Cancer. Int J Mol Sci 2020;21:E3877. [PMID: 32485921 DOI: 10.3390/ijms21113877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
84 Scarpignato C, Tolone S. Addressing long-term PPI safety. Digestive and Liver Disease 2020;52:853-6. [DOI: 10.1016/j.dld.2020.05.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Savarino E, Marabotto E, Zentilin P, Furnari M, Bodini G, Pellegatta G, Lorenzon G, Della Coletta M, Ghisa M, Coppo C, Marinelli C, Savarino V. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety 2018;17:785-94. [DOI: 10.1080/14740338.2018.1497155] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
86 Bian J, Wang A, Lin J, Wu L, Huang H, Wang S, Yang X, Lu X, Xu Y, Zhao H. Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis. Medicine (Baltimore) 2017;96:e6723. [PMID: 28445288 DOI: 10.1097/MD.0000000000006723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
87 Abbas MK, Zaidi ARZ, Robert CA, Thiha S, Malik BH. The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review. Cureus 2019;11:e5563. [PMID: 31523592 DOI: 10.7759/cureus.5563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
88 Sivasubramaniam R, Harvey RJ. How to Assess, Control, and Manage Uncontrolled CRS/Nasal Polyp Patients. Curr Allergy Asthma Rep 2017;17:58. [PMID: 28770480 DOI: 10.1007/s11882-017-0728-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
89 Tansey P, Shiels P. Inappropriate prescribing of proton pump inhibitors (PPI) in patients > 65 years at a level 2 Irish hospital. Ir J Med Sci 2021;190:853-4. [PMID: 32910401 DOI: 10.1007/s11845-020-02368-3] [Reference Citation Analysis]
90 Wahking RA, Steele RL, Hanners RE, Lockwood SM, Davis KW. Outcomes From a Pharmacist - led Proton Pump Inhibitor Stewardship Program at a Single Institution. Hosp Pharm 2018;53:59-67. [PMID: 29434389 DOI: 10.1177/0018578717747192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
91 Shao YJ, Chan T, Tsai K, Wu S. Association between proton pump inhibitors and the risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:460-8. [DOI: 10.1111/apt.14835] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
92 Tosetti C, Nanni I. Use of proton pump inhibitors in general practice. World J Gastrointest Pharmacol Ther 2017; 8(3): 180-185 [PMID: 28828196 DOI: 10.4292/wjgpt.v8.i3.180] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
93 Morschel CF, Mafra D, Eduardo JCC. The relationship between proton pump inhibitors and renal disease. J Bras Nefrol 2018;40:301-6. [PMID: 30010692 DOI: 10.1590/2175-8239-jbn-2018-0021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Cooper CA, Urso PP. Gastroesophageal Reflux in the Intensive Care Unit Patient. Crit Care Nurs Clin North Am 2018;30:123-35. [PMID: 29413207 DOI: 10.1016/j.cnc.2017.10.011] [Reference Citation Analysis]
95 Lee L, Ramos-Alvarez I, Ito T, Jensen RT. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome. Int J Mol Sci 2019;20:E5128. [PMID: 31623145 DOI: 10.3390/ijms20205128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
96 Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, Poetker DM, Soler Z, Welch KC, Wise SK, Adappa N, Alt JA, Anselmo-Lima WT, Bachert C, Baroody FM, Batra PS, Bernal-Sprekelsen M, Beswick D, Bhattacharyya N, Chandra RK, Chang EH, Chiu A, Chowdhury N, Citardi MJ, Cohen NA, Conley DB, DelGaudio J, Desrosiers M, Douglas R, Eloy JA, Fokkens WJ, Gray ST, Gudis DA, Hamilos DL, Han JK, Harvey R, Hellings P, Holbrook EH, Hopkins C, Hwang P, Javer AR, Jiang RS, Kennedy D, Kern R, Laidlaw T, Lal D, Lane A, Lee HM, Lee JT, Levy JM, Lin SY, Lund V, McMains KC, Metson R, Mullol J, Naclerio R, Oakley G, Otori N, Palmer JN, Parikh SR, Passali D, Patel Z, Peters A, Philpott C, Psaltis AJ, Ramakrishnan VR, Ramanathan M Jr, Roh HJ, Rudmik L, Sacks R, Schlosser RJ, Sedaghat AR, Senior BA, Sindwani R, Smith K, Snidvongs K, Stewart M, Suh JD, Tan BK, Turner JH, van Drunen CM, Voegels R, Wang Y, Woodworth BA, Wormald PJ, Wright ED, Yan C, Zhang L, Zhou B. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 2021;11:213-739. [PMID: 33236525 DOI: 10.1002/alr.22741] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 22.0] [Reference Citation Analysis]
97 Graham DY, Tansel A. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol 2018;16:800-808.e7. [PMID: 28964908 DOI: 10.1016/j.cgh.2017.09.033] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 12.8] [Reference Citation Analysis]
98 Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel H, Lip GYH, Deneke T, Dagres N, Boriani G, Chao TF, Choi EK, Hills MT, Santos IS, Lane DA, Atar D, Joung B, Cole OM, Field M; External reviewers:. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021:euab065. [PMID: 33895845 DOI: 10.1093/europace/euab065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
99 Puchon E, Goboova M, Vano I, Fazekas T, Javorova-rihova Z, Kuzelova M. Medication-related factors associated with proton pump inhibitor prescription beyond official guidelines in older adults. Eur Geriatr Med 2020;11:1051-61. [DOI: 10.1007/s41999-020-00380-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol 2018;11:1123-34. [PMID: 30295105 DOI: 10.1080/17512433.2018.1531703] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 15.3] [Reference Citation Analysis]
101 Vatcharavongvan P, Puttawanchai V. Potentially inappropriate medications among the elderly in primary care in Thailand from three different sets of criteria. Pharm Pract (Granada) 2019;17:1494. [PMID: 31592037 DOI: 10.18549/PharmPract.2019.3.1494] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
102 Franceschelli S, Gatta DMP, Pesce M, Ferrone A, Di Martino G, Di Nicola M, De Lutiis MA, Vitacolonna E, Patruno A, Grilli A, Felaco M, Speranza L. Modulation of the oxidative plasmatic state in gastroesophageal reflux disease with the addition of rich water molecular hydrogen: A new biological vision. J Cell Mol Med 2018;22:2750-9. [PMID: 29512923 DOI: 10.1111/jcmm.13569] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
103 Gyawali CP. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe. Curr Gastroenterol Rep 2017;19. [DOI: 10.1007/s11894-017-0586-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
104 Scarpignato C, Bjarnason I. Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition. Curr Gastroenterol Rep. 2019;21:55. [PMID: 31720893 DOI: 10.1007/s11894-019-0726-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
105 Wang H, Shao F, Liu X, Xu W, Ou N, Qin X, Liu F, Hou X, Hu H, Jiang J. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control. Br J Clin Pharmacol 2019;85:2547-58. [PMID: 31332820 DOI: 10.1111/bcp.14076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
106 Douwes RM, Gomes-Neto AW, Eisenga MF, Van Loon E, Schutten JC, Gans ROB, Naesens M, van den Berg E, Sprangers B, Berger SP, Navis G, Blokzijl H, Meijers B, Bakker SJL, Kuypers D. The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study. PLoS Med 2020;17:e1003140. [PMID: 32542023 DOI: 10.1371/journal.pmed.1003140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
107 Juntunen H, Taipale H, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S, Tiihonen M. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease. Eur J Clin Pharmacol 2017;73:1149-58. [PMID: 28577224 DOI: 10.1007/s00228-017-2273-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
108 Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017;11:CD011194. [PMID: 29161458 DOI: 10.1002/14651858.CD011194.pub3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
109 Cucchi D, Menon A, Feroldi FM, Boerci L, Randelli PS. The presence of gastroesophageal reflux disease increases the risk of developing postoperative shoulder stiffness after arthroscopic rotator cuff repair. J Shoulder Elbow Surg 2020;29:2505-13. [PMID: 32711105 DOI: 10.1016/j.jse.2020.07.002] [Reference Citation Analysis]
110 Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Hunt RH. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci 2020;1482:193-212. [PMID: 32935346 DOI: 10.1111/nyas.14473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Davis KW, Hanners RE, Lockwood SM. Implementation of a proton pump inhibitor stewardship program. American Journal of Health-System Pharmacy 2017;74:932-7. [DOI: 10.2146/ajhp160670] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
112 Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 42] [Article Influence: 27.5] [Reference Citation Analysis]
113 Hunt R, B Lazebnik L, C Marakhouski Y, Manuc M, Gn R, S Aye K, S Bordin D, V Bakulina N, S Iskakov B, A Khamraev A, M Stepanov Y, Ally R, Garg A. International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G. Euroasian J Hepatogastroenterol 2018;8:148-60. [PMID: 30828557 DOI: 10.5005/jp-journals-10018-1281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
114 Hu J, Liu R, Yu X, Li Z, Liu X, Hao Y, Zhu N, Kang J, Li Y. Protective Effects of Small-Molecule Oligopeptides Isolated from Tilapia Fish Scale on Ethanol-Induced Gastroduodenal Injury in Rats. Nutrients 2021;13:2078. [PMID: 34204516 DOI: 10.3390/nu13062078] [Reference Citation Analysis]
115 Gatta L, Scarpignato C. Editorial: Helicobacter pylori resistance and sequential therapy-authors’ reply. Aliment Pharmacol Ther 2018;48:96-7. [DOI: 10.1111/apt.14676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Daniels B, Pearson SA, Buckley NA, Bruno C, Zoega H. Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016. Therap Adv Gastroenterol 2020;13:1756284820913743. [PMID: 32218806 DOI: 10.1177/1756284820913743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
117 Qorraj-Bytyqi H, Hoxha R, Sadiku S, Bajraktari IH, Sopjani M, Thaçi K, Thaçi S, Bahtiri E. Proton Pump Inhibitors Intake and Iron and Vitamin B12 Status: A Prospective Comparative Study with a Follow up of 12 Months. Open Access Maced J Med Sci 2018;6:442-6. [PMID: 29610598 DOI: 10.3889/oamjms.2018.142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
118 Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
119 Chen F, Jiang H, Xu J, Wang S, Meng D, Geng P, Dai D, Zhou Q, Zhou Y. In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine. Drug Des Devel Ther 2020;14:4815-24. [PMID: 33204067 DOI: 10.2147/DDDT.S276704] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Alkhathami AM, Alzahrani AA, Alzhrani MA, Alsuwat OB, Mahfouz MEM. Risk Factors for Gastroesophageal Reflux Disease in Saudi Arabia. Gastroenterology Res 2017;10:294-300. [PMID: 29118870 DOI: 10.14740/gr906w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
121 Corsonello A, Lattanzio F. Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe? Trends in Cardiovascular Medicine 2019;29:353-60. [DOI: 10.1016/j.tcm.2018.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
122 Baltz AP, Gressler LE, Costantino RC, Mcpherson ML. Nonprescription Medication Use in Hospice Patients. Am J Hosp Palliat Care 2020;37:336-42. [DOI: 10.1177/1049909119876259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Bell R, Lipham J, Louie B, Williams V, Luketich J, Hill M, Richards W, Dunst C, Lister D, McDowell-Jacobs L, Reardon P, Woods K, Gould J, Buckley FP, Kothari S, Khaitan L, Smith CD, Park A, Smith C, Jacobsen G, Abbas G, Katz P. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. Gastrointest Endosc. 2019;89:14-22.e1. [PMID: 30031018 DOI: 10.1016/j.gie.2018.07.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 16.0] [Reference Citation Analysis]